A year after guidelines were revised to remove the use of race in eGFR, many labs and pathologists were still relying on the ...
Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...
Older adults with advanced kidney disease are often motivated to receive a transplant but may face emotional and psychosocial ...
The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...
Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with ...
Chronic kidney disease is a common complication for people living with type 2 diabetes. Diabetes is the leading cause of ...
Kidney disease affects millions of Americans, with Black communities facing disproportionately higher risks due to genetic factors, socioeconomic challenges, ...
Body weight cycling, also known as “yo-yo dieting,” is associated with a 25%-36% increased risk for diabetic kidney disease ...
They eventually landed at the University of Virginia Children’s Hospital where Kamden was diagnosed with nephrotic syndrome, ...
A multi-disciplinary team of experts has commenced an essential research project aimed at understanding and addressing the ...